A Randomized, db, Placebo Controlled Parallel Group Efficacy and Safety Study Over 24 Weeks in T2D Patients in China
收藏DataCite Commons2025-12-08 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00003621/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
In this randomised, double-blind, parallel group trial, the safety and efficacy of 5 mg of Linagliptin administered orally once daily will be compared with a placebo after 24 weeks of treatment in monotherapy in patients with type 2 diabetes and insufficient glycaemic control.
本项随机双盲平行组临床试验，拟纳入血糖控制不佳的2型糖尿病患者，予每日一次口服5mg利格列汀（Linagliptin）或安慰剂单药治疗，持续24周，对比二者的安全性与有效性。
提供机构：
Vivli
创建时间：
2019-04-12
